AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20639026 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg serlopitant
Number of subjects: 557
Study 20639026 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg serlopitant
Number of subjects: 557
Study 20639026 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg serlopitant
Number of subjects: 557
Study 20639026 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tolterodine
Number of subjects: 557
Study 20639026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study 20639026 — intervention group
Group type: EXPERIMENTAL
Intervention: Serlopitant (all doses)
Number of subjects: 557
Study 20639026 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 557
Study 20639026 — intervention group
Group type: EXPERIMENTAL
Intervention: Serlopitant
Number of subjects: 557
Study 17661544 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive group psychotherapy
Number of subjects: 0
Study 17661544 — intervention group
Group type: COMPARATOR
Intervention: Supportive group psychotherapy
Number of subjects: 0
Study 17661544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interpretive and supportive group psychotherapy
Number of subjects: 0
Study 16246964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg, n=19)
Number of subjects: 35
Study 16246964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 35
Study 12072897 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 22
Study 12072897 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) and long-chain triglycerides (LCT)
Number of subjects: 22
Study 10084097 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 30
Study 10084097 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO
Number of subjects: 30
Study 10084097 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 30
Study 7727326 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine plus 1 microgram/kg fentanyl (group A)
Number of subjects: 11
Study 7727326 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine plus 1 microgram/kg fentanyl (group B)
Number of subjects: 11
Study 1746730 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed peritoneal lavage
Number of subjects: 220
Study 1746730 — intervention group
Group type: COMPARATOR
Intervention: Open peritoneal lavage
Number of subjects: 220
Study 6642921 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (ex-mental patient in the process of rehabilitation)
Number of subjects: 72
Study 6642921 — intervention group
Group type: COMPARATOR
Intervention: Group II (ex-mental patient who had successfully completed rehabilitation)
Number of subjects: 72
Study 6642921 — intervention group
Group type: COMPARATOR
Intervention: Group III (normal person)
Number of subjects: 72
Study 31060760 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg racemic ketamine + 0.5 mg/kg midazolam (K-4 group)
Number of subjects: 90
Study 31060760 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg racemic ketamine + 0.5 mg/kg midazolam (K-6 group)
Number of subjects: 90
Study 31060760 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg racemic ketamine + 0.5 mg/kg midazolam (K-8 group)
Number of subjects: 90
Study 29468633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin (PG)
Number of subjects: 184
Study 29468633 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 184
Study 26154337 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 18
Study 26154337 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIE)
Number of subjects: 18
Study 26154337 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 18
Study 24763694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic antimicrobial peptide LL-37 at sub-inhibitory concentrations
Number of subjects: 0
Study 24763694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic antimicrobial peptide LL-37
Number of subjects: 0
Study 24763694 — intervention group
Group type: COMPARATOR
Intervention: Reactive oxygen species
Number of subjects: 0
Study 24763694 — intervention group
Group type: COMPARATOR
Intervention: Polymorphonucleocytes (PMNs)
Number of subjects: 0
Study 22138444 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (30 minute workouts, 5 times/week for 16 weeks)
Number of subjects: 212
Study 22138444 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 212
Study 19844249 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of estrogen therapy
Number of subjects: 0
Study 19844249 — intervention group
Group type: EXPERIMENTAL
Intervention: Late initiation of estrogen therapy
Number of subjects: 0
Study 19844249 — intervention group
Group type: COMPARATOR
Intervention: Estrogen therapy
Number of subjects: 0
Study 17851781 — intervention group
Group type: EXPERIMENTAL
Intervention: D(2) dissection
Number of subjects: 1316
Study 17851781 — intervention group
Group type: EXPERIMENTAL
Intervention: D(2) dissection with splenectomy (or pancreatico‐splenectomy)
Number of subjects: 1316
Study 17851781 — intervention group
Group type: COMPARATOR
Intervention: D(1) dissection
Number of subjects: 1316
Study 15933313 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate treatment in trial participants (Magpie Trial)
Number of subjects: 408
Study 15933313 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 408
Study 11753162 — intervention group
Group type: EXPERIMENTAL
Intervention: Pureed beef
Number of subjects: 18
Study 11753162 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified infant rice cereal
Number of subjects: 18
Study 11753162 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of human milk to beef
Number of subjects: 18
Study 11753162 — intervention group
Group type: COMPARATOR
Intervention: Addition of human milk to cereal
Number of subjects: 18
Study 10366994 — intervention group
Group type: EXPERIMENTAL
Intervention: clopidogrel 75 mg once daily for 11 days
Number of subjects: 30
Study 10366994 — intervention group
Group type: COMPARATOR
Intervention: naproxen 250 mg b.i.d. for 7 days + placebo for 11 days
Number of subjects: 30
Study 10366994 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 250 mg b.i.d. for 7 days + clopidogrel 75 mg once daily for 11 days
Number of subjects: 30
Study 10366994 — intervention group
Group type: COMPARATOR
Intervention: naproxen + placebo
Number of subjects: 30
Study 10366994 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen + clopidogrel
Number of subjects: 30
Study 8032704 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 355
Study 8032704 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg
Number of subjects: 355
Study 8032704 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (both doses)
Number of subjects: 355
Study 3187474 — intervention group
Group type: COMPARATOR
Intervention: Vitalograph Compact (C)
Number of subjects: 20
Study 3187474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitalograph Alpha (A)
Number of subjects: 20
Study 29847222 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-Based Health Coaching (VC)
Number of subjects: 30
Study 29847222 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person Health Coaching (IP)
Number of subjects: 30
Study 29847222 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 28221048 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed message about PBS use
Number of subjects: 62
Study 28221048 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed message about PBS use
Number of subjects: 62
Study 28221048 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 62
Study 25673206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook double balloon dilation (Cook group)
Number of subjects: 55
Study 25673206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic injection of ethacridine lactate (EL group)
Number of subjects: 55
Study 22510992 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cleansing
Number of subjects: 1923
Study 22510992 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cleansing
Number of subjects: 1923
Study 22510992 — intervention group
Group type: COMPARATOR
Intervention: No chlorhexidine
Number of subjects: 1923
Study 20074228 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicyclic acid (ASA), acetaminophen, and caffeine
Number of subjects: 0
Study 20074228 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with single substances (ASA, acetaminophen, or caffeine)
Number of subjects: 0
Study 17450358 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information sheet explaining the risks of surgery (group 2)
Number of subjects: 53
Study 17450358 — intervention group
Group type: COMPARATOR
Intervention: Routine consent with verbal explanations (group 1)
Number of subjects: 53
Study 16205558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (0.3 mg)
Number of subjects: 64
Study 16205558 — intervention group
Group type: COMPARATOR
Intervention: Usual care (sham injections)
Number of subjects: 64
Study 11839850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 20
Study 11839850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10424554 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate arthroscopic stabilization (group S)
Number of subjects: 40
Study 10424554 — intervention group
Group type: COMPARATOR
Intervention: Immobilization for 3 weeks followed by rehabilitation (group T)
Number of subjects: 40
Study 7749987 — intervention group
Group type: COMPARATOR
Intervention: Group R (cold storage workers)
Number of subjects: 18
Study 7749987 — intervention group
Group type: COMPARATOR
Intervention: Group C (general storehouse workers)
Number of subjects: 18
Study 1691382 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 x 80 mg/day)
Number of subjects: 7
Study 1691382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (2 x 10 mg/day)
Number of subjects: 7
Study 1691382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6777653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation (IVH)
Number of subjects: 0
Study 30895944 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol plus 5‐fluorouracil (5‐FU)
Number of subjects: 70
Study 30895944 — intervention group
Group type: COMPARATOR
Intervention: Vaseline plus 5‐fluorouracil (5‐FU) (control)
Number of subjects: 70
Study 28755244 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min quitting advice from youth counselors and a 12-page self-help smoking cessation booklet
Number of subjects: 831
Study 28755244 — intervention group
Group type: COMPARATOR
Intervention: 12-page self-help smoking cessation booklet
Number of subjects: 831
Study 26490488 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for postgraduate physicians, duration: three days
Number of subjects: 0
Study 26490488 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25237122 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone
Number of subjects: 14
Study 25237122 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxycodone
Number of subjects: 14
Study 25237122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22641495 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocele repair (varicocelectomy)
Number of subjects: 136
Study 22641495 — intervention group
Group type: COMPARATOR
Intervention: Expectant therapy
Number of subjects: 136
Study 20078852 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Training System for home rehabilitation
Number of subjects: 46
Study 20078852 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapeutic training
Number of subjects: 46
Study 17651518 — intervention group
Group type: EXPERIMENTAL
Intervention: TRL derived from high-oleic sunflower oil (HOSO)
Number of subjects: 9
Study 17651518 — intervention group
Group type: COMPARATOR
Intervention: TRL derived from virgin olive oil (VOO)
Number of subjects: 9
Study 17651518 — intervention group
Group type: EXPERIMENTAL
Intervention: TRL derived from virgin olive oil enriched with minor components (EVO)
Number of subjects: 9
Study 15850733 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 14
Study 15850733 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 14
Study 15850733 — intervention group
Group type: COMPARATOR
Intervention: Skin prick
Number of subjects: 14
Study 12417866 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids
Number of subjects: 0
Study 12417866 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10611883 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg per day
Number of subjects: 84
Study 10611883 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg per day
Number of subjects: 84
Study 10611883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 10611883 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 84
Study 10611883 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 84
Study 10611883 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen, Indomethacin, Placebo
Number of subjects: 84
Study 7727328 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric tetracaine (IT) at varying doses and volumes
Number of subjects: 120
Study 7727328 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric tetracaine (IT) at constant volume
Number of subjects: 120
Study 2328752 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme potentiated desensitising vaccine (single injection in March)
Number of subjects: 0
Study 2328752 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7011357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chlorpheniramine and cimetidine
Number of subjects: 20
Study 7011357 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine alone
Number of subjects: 20
Study 7011357 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 20
Study 7011357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29177920 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, low-literacy intervention (photonovella and DVD plus fecal immunochemical test [FIT])
Number of subjects: 270
Study 29177920 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-targeted intervention (standard educational brochure plus FIT)
Number of subjects: 270
Study 27824234 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm aerobic exercise (3 days/week; 1.5 hours/week at 50‐70% pVO2) for 12 weeks
Number of subjects: 33
Study 27824234 — intervention group
Group type: COMPARATOR
Intervention: General exercises only (2 sessions/day; 5 days/week)
Number of subjects: 33
Study 26717366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (25mg qd for 10 days between cycles) combined with docetaxel (40 mg) and cisplatin (50 mg) for 12 cycles (24 weeks) followed by maintenance vinorelbine (30mg TIW) until disease progression
Number of subjects: 6
Study 26717366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib combined with chemotherapy
Number of subjects: 6
Study 26227903 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic hormonal fertility monitor (EHFM)
Number of subjects: 357
Study 26227903 — intervention group
Group type: COMPARATOR
Intervention: Cervical mucus monitoring (CMM)
Number of subjects: 357
Study 22577293 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement 20070721-GX
Number of subjects: 44
Study 19485723 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 300
Study 19485723 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 300
Study 18949216 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg PZQ + 6 mg/kg AM
Number of subjects: 0
Study 18949216 — intervention group
Group type: COMPARATOR
Intervention: 60 mg/kg PZQ + AM placebo
Number of subjects: 0
Study 18949216 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/kg PZQ + 6 mg/kg AM
Number of subjects: 0
Study 18949216 — intervention group
Group type: COMPARATOR
Intervention: 120 mg/kg PZQ + AM placebo
Number of subjects: 0
Study 15691272 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 0.06% three times per day for 6 months
Number of subjects: 40
Study 15691272 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1% tapered within 6 months
Number of subjects: 40
Study 12073766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate (40 mg orally twice a day)
Number of subjects: 217
Study 12073766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 12073766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate
Number of subjects: 217
Study 10432913 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder intervention group
Number of subjects: 0
Study 10432913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postcard)
Number of subjects: 0
Study 7719178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 12
Study 7719178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2396469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero OPV
Number of subjects: 305
Study 2396469 — intervention group
Group type: COMPARATOR
Intervention: PMK OPV
Number of subjects: 305
Study 32007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide twice a day plus atenolol, metoprolol, pindolol and propranolol in single daily doses
Number of subjects: 0
Study 32007 — intervention group
Group type: EXPERIMENTAL
Intervention: Each beta‐adrenoreceptor‐blocking drug
Number of subjects: 0
Study 30649176 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg Ca/d)
Number of subjects: 64
Study 30649176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28429343 — intervention group
Group type: COMPARATOR
Intervention: McDonald's® Meal (McDM)
Number of subjects: 22
Study 28429343 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald's® Meal (McDM) + Hazelnut (H)
Number of subjects: 22
Study 28429343 — intervention group
Group type: COMPARATOR
Intervention: No Dietary Treatment (NDT)
Number of subjects: 22
Study 26362830 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 134
Study 26362830 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 134
Study 23700341 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight loss (BMI < 18 kg/m²)
Number of subjects: 1309
Study 23700341 — intervention group
Group type: COMPARATOR
Intervention: No weight loss (BMI ≥ 18 kg/m²)
Number of subjects: 1309
Study 21881528 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine ± Perindopril
Number of subjects: 3666
Study 21881528 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 3666
Study 21881528 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous use of aspirin
Number of subjects: 3666
Study 21881528 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SBP strata (151-160, 161-170, 171-180, >180 mmHg)
Number of subjects: 3666
Study 21881528 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score developed
Number of subjects: 3666
Study 19664426 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC level 0.08%
Number of subjects: 24
Study 19664426 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC level 0.05%
Number of subjects: 24
Study 19664426 — intervention group
Group type: EXPERIMENTAL
Intervention: High task demand (offset weave)
Number of subjects: 24
Study 19664426 — intervention group
Group type: EXPERIMENTAL
Intervention: High time pressure (hazard avoidance for near obstacles)
Number of subjects: 24
Study 19664426 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained tolerances (circuit track)
Number of subjects: 24
Study 17938794 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus infusion (BI) of rFVIIa (90 microg/kg every 2 hours during surgery through day 5, then every 4 hours for days 6-10)
Number of subjects: 24
Study 17938794 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of rFVIIa (50 microg/kg/h through day 5, then 25 microg/kg/h for days 6-10)
Number of subjects: 24
Study 17938794 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving FVIII or FIX concentrates
Number of subjects: 24
Study 15359923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m DTPA aerosol lung scintigraphy in PSP patients
Number of subjects: 13
Study 15359923 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99m DTPA aerosol lung scintigraphy in healthy controls
Number of subjects: 13
Study 15359923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m DTPA aerosol lung scintigraphy in apical parts of lungs
Number of subjects: 13
Study 15359923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m DTPA aerosol lung scintigraphy in basal parts of lungs
Number of subjects: 13
Study 15359923 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of clearance rate of Tc‐99m DTPA with PFT results
Number of subjects: 13
Study 15359923 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of clearance rate of Tc‐99m DTPA with recurrence rate of PSP
Number of subjects: 13
Study 15359923 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of clearance rate of Tc‐99m DTPA with percentage of pneumothorax
Number of subjects: 13
Study 11780862 — intervention group
Group type: EXPERIMENTAL
Intervention: Repinotan (0.5 mg/day)
Number of subjects: 60
Study 11780862 — intervention group
Group type: EXPERIMENTAL
Intervention: Repinotan (1.25 mg/day)
Number of subjects: 60